Core Insights - Medpace Holdings, Inc. is under investigation for potential securities law claims due to discrepancies between public statements and internal data regarding its clinical-trial booking pipeline [1] - The company reported a Q4 2025 book-to-bill ratio of 1.04, significantly lower than its historical range of 1.10 to 1.25, indicating a concerning trend in business health [1] - Following the earnings report, Medpace shares dropped approximately 15.9%, primarily attributed to the bookings miss [1] Company Performance - Medpace reported Q4 2025 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding consensus estimates [1] - The ending backlog as of December 31, 2025, was approximately $3 billion, reflecting a modest year-over-year growth of 4.3% [1] Industry Context - The book-to-bill ratio is a critical forward-looking indicator in the contract research organization (CRO) sector, with significant implications for valuation and investor expectations [1] - The CRO industry experienced record demand post-pandemic, making any decline in booking momentum particularly impactful for investor assessments of future growth [1]

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The company's shares fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - The decline in stock price was attributed to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to a sharp decline in stock price and raising concerns about future demand [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. - The timing of these transactions is relevant to the ongoing investigation [4]. Analyst Commentary - Analysts questioned management about the nature of booking deterioration during the Q4 earnings call, highlighting concerns over direct-fee growth and cancellation levels [5]. - Management acknowledged that the level of cancellations was the highest compared to the previous year, describing them as "broad-based" without providing clear reasons [5].

Core Insights - CGI Group reported strong first-quarter fiscal 2026 results, with increased revenue, a book-to-bill ratio above 1.0, and record operating cash flow despite challenges from a U.S. federal government shutdown and a one-time cost in India [1] Financial Results and Regional Performance - CGI achieved CAD 4.1 billion in revenue, reflecting a year-over-year increase of 7.7%, or 3.4% when excluding foreign exchange impacts, driven by acquisitions and demand from the APAC delivery center, which grew by 5.8% [2] - U.S. operations were impacted by a federal shutdown, but management anticipates sequential improvement in the next quarter, describing the U.S. federal segment as operating in a "very dynamic environment" [2] Bookings, Backlog, and Mix - Quarterly bookings reached CAD 4.5 billion, resulting in a book-to-bill ratio of 110%, with managed services leading at 117% and systems integration and consulting at 100% [3] - Excluding U.S. federal bookings, the combined book-to-bill ratio was 118% [3] Trailing 12-Month Performance - On a trailing 12-month basis, CGI's total book-to-bill ratio stood at 110%, with North America at 122% and Europe at 101%, while the contracted backlog reached CAD 31.3 billion, equating to 1.9 times revenue [4] Regional Growth Highlights - The UK and Australia experienced a growth of 31%, attributed to the transformative acquisition of BJSS [5] - Western and Southern Europe saw a growth of 9%, driven by the acquisition of Apside, which includes engineering services [5] - U.S. commercial and state government bookings were at 169%, while Finland, Poland, and the Baltics recorded 124%, and Scandinavia, Northwest, and Central East Europe achieved 113% [6] Overall Bookings Performance - Quarterly bookings increased by over CAD 300 million year over year, with just over half from new awards and add-ons, and a win rate on renewals exceeding 95% [7] - Total bookings on a trailing 12-month basis rose by 12% to nearly CAD 18 billion, with managed services bookings increasing by 16% [7]

Core Insights - Alstom recorded EUR 20 billion in orders for the first nine months of fiscal year 2025 and 2026, with a book-to-bill ratio of 1.4, which accelerated to 2 in the third quarter, leading to a backlog of EUR 100.3 billion, an increase from EUR 96 billion at the end of September [2]. Group 1: Orders and Sales Performance - The Americas are on track for their best year ever in terms of commercial momentum, with significant orders from Mexico and Canada this quarter, in addition to large orders from New York and New Jersey booked in the first half [2]. - Europe remains the largest contributor to Alstom's orders, supported by numerous rolling stock options being exercised in France and first-time orders in Central and Eastern Europe [3].